LITERATURE
1.
ZINBERG,N.E.: Drug, set and setting: the basis for controlled
intoxicant use. New Haven, Yale University Press, 1984.
2.
MARK & IRVING: Violence and the brain. 1970; cited in:
3.
PATTERSON,D.: The violence of psychosurgery. New Scientist, 8
febr. 1979, 374-376.
4.
LIDBERG,L.TUCK,J.R.,ASBERG,M., SCALIA-TOMBA,G.P. &
BERTILSSON,L.: Homicide, suicide and CSF 5-HIAA. Acta
Psychiatrica Scandinavica, 1985, 71(3):230-236.
5.
TABAKOFF,B.,HOFFMAN,P.L. & PETERSEN,R.C.: Advances in
neurochemistry, a leading edge of alcohol research. Alcohol
health & Research world, 1990, 14(2):138-143
6.
SHUSTER,L.: Genetics of responses to drugs of abuse.
Int.J.Addictions, 25(1A)57-79 (1990-91)
7.
ERIKSSON,P.S., RöNNBäCK,L., & HANSSON,E.: Do persistent
morphine effects involve interactions with the genome? Drug and
Alcohol Dependence, 1989, 24;39-43.
8.
LINDESMITH,A.: Can chimpansees become addicts? J..Compar.Psychol.
39; 1946
9.
SPRAGG,S.D.S.: Morphine addiction in Chimpansees. Comparative
Psychology Monograph 15, no 7, 1940
10.
DE KORT,M.: Medische professionals en hùn drugs. Verzorging, 4
(1989) 2:20-32
11.
MERLIN, M.D.: On the trail of the ancient opium poppy. Associated
University Presses, Cranbury, 1984.
12.
BERRIDGE,V. & RAWSON,N.S.B.: Opiate use and legislative
control: a nineteenth century case study. Social Science and
Medicine, 1979; 13A(3): 351-363.BERRIDGE,V.& EDWARDS,G.:
Opium and the people. Allan Lane, London, 1981 BERRIDGE,V.:
Opium. In:Polak,F.& Miks,T.: Dokters en dope. NIAD, 1994
13.
W.ELLIOTT, cit. in: JUDSON,H.F.: Heroin addiction in Britain.
Harcourt Brace Jovanovich, New York, 1974
14.
MUSTO,D.: The American disease. Yale University Press, New Haven,
1973
15.
TAYLOR,A.H.: American diplomacy and the narcotics traffic,
1900-1939. Duke University Press, 1969.
16.
McCOY, A.F.: The politics of heroin: CIA complicity in the global
drug trade. Lawrence Hill Books, Brooklyn N.Y., 1991
17.
DRUMMOND D.C. et al.: Chlordiazepoxide vs. methadone in opiate
withdrawal: a preliminary double blind trial. Drug and Alcohol
dependence, 23 (1989) 63-71
18.
ARIF,A. & WESTERMEYER,J.: Methadone in the management of
opioid dependence. Programs and policies around the world. New
York, Praeger, 1990
19.
DOLE, V.P. & M.E.NYSWANDER: Rehabilitation of heroin addicts
after blockade with methadone. New York State Journal of
Medicine, 1 augustus 1966
20.
DOLE,V.P.,M.E.NYSWANDER, M.J.CREEK: Narcotic blockade
Arch.Intern.Med., 1966, 118.
21.
DOLE,V.P.,M.E.NYSWANDER: The use of methadone for Narcotic
Blockade. Br.J.Addict. 1968, 63;55-57.
22.
GEARING,F.R.: Evaluation of methadone maintenance program.
Intern.J.Addict.,1970,5;517.
23.
GEARING,F.R. & M.D.SCHWEITZER: An epidemiologic evaluation of
long-term methadone maintenance treatment for heroin. Am.J. of
Epidemiology, 1974, vol.100.
24.
VOSSENBERG,P.: Methadon informatie, CAD De IJsselstreek, 1989.
25.
TRIMBOS,C.J.B.J.: De methadon-onderhoudsbehandeling van
heroine-verslaving. Ned.Tijdschr.Geneesk. 1971,115;7.
26.
MADDUX,J.F.& C.L.BOWDEN: Critique of success with methadone
treatment. Am.J.Psychiat. 1972, 127:4:440-446.
27.
PREBLE, E. & Th.MILLER: Methadone, wine and welfare. uit:
R.S.Weppner (ed.): Street ethnography, Sage Publications, 1977.
28.
HADDOX,V.G.& M.D.JACOBSON: Psychological adjustment - Mood
and personality fluctuations of long term methadon maintenance
patients. Intern.J.Addict. 1972, 7:4, 619-627.
29.
FROMBERG,E., A.HAVAS & G.HAVERKAMP Jaarverslag Stichting
Kontakt Sentra, Amsterdam, 1977.
30.
PREBLE,E. & J.J.CASEY: Taking care of bussiness: the heroine
user's life on the street. Uit: D.Smith & G.R.Gay (eds): It's
so good, don't even try it once, Heroin in perspective. New
Yersey, Prentice-Hall Inc. 1972.
31.
ALEXANDER,B.K. & P.E.HADAWAY: Theories of opiate addiction:
Time for pruning? J.Drug Issues, 1981;11:1.
32.
SOLOWAY, I.H.:Methadon and the culture of addiction. J.
Psychedelic Drugs 1974; 6:91-99.
33.
NOORLANDER,E.: Intentional and unintentional effects of the Dutch
methadone system. In Ch.D.Kaplan & M.Kooyman (eds):
Proceedings of the 15th International Institute on the Prevention
and Treatment of drugdependence of the I.C.A.A. Erasmus
Universiteit, Rotterdam, 1987.
34.
De MUG,W.: Heroine: een geneesmiddel of een genotmiddel.
(T.Alc.Drugs, 1984, 10(4):171-173.
35.
FROMBERG,E.: Moeten we het verdrag opzeggen? Aloha, 18,15-18.
36.
VAN EPEN,J.H.: Compendium drugverslaving en alcoholisme.
Elsevier, Amsterdam, 1978
37.
ISBELL,H.: Addiction to barbiturates and the barbiturate
abstinence syndrome, Ann.Int.Med., 1950,33,108
38.
FREZZA M., PADOVA C. di, POZZATO G.: High blood alcohol levels in
women. New Engl. J. Med. 1990; 322; 95-99.
39.
BLUM K., HAMILTON M.G., MEYER E.K.: Isoquinoline alkaloids as
possible regulators of alcohol addiction. Lancet 1977; I:799-800
40.
JEFFCOATE W.J., et al.: Prevention of effects of alcohol
intoxication by naloxone. Lancet, 1979, vol II:1157-1159
41.
PAUL,S.: Science, 1986, vol. 234, blz. 1243 ev.
42.
SUZDAK,P.D., GLOWA,J.R., CRAWLEY,J.N., SCHWARTZ,R.D., SKOLNICK,P.
& PAUL,S.M.: A selective imidazobenzo-diazepine antagonist of
ethanol in the rat. Science, 1986, vol. 234, blz. 1243-1247.
43.
SCHUCKIT,M.A.: The importance of genetic factors in alcoholism.
Drug abuse & alcoholism newsletter, 1989, vol. 18:1.
44.
NEWLIN,D.B. & THOMSON,J.B.: Chronic tolerance and
sensitization to alcohol in sons of alcoholics. Alcoholism: Clin.
Exper. Res. 1991, 15:3; 399-405
45.
HWANG,B.H.; LUMENG,L.; WU,J.-Y. & LI,T.-K.: Increased number
of GABA-ergic terminals in the nucleus accumbens is associated
with alcohol preference in rats. Alcoholism: clinical and
experimental research 1990, 14:3, 503-507
46.
UUSI-OUKARI,M. & KORPI,E.R.: Specific alterations in the
cerebellar GABA-a receptors of an alcohol-sensitive ANT rat line.
Alcoholism, Clin. Exper. Res. 1991 15:2; 241-248.
47.
CRABB,D.W.: Molecular cloning in alcohol research. Alcohol health
& Research world. 1990, 14:3; 197-203
48. Int.J.Drug Policy, 1990
49.
JACKSON,J.G.: Letter; New Engl.J.Med. 1990. 321(13):907
50.
MANTEGAZZA: Sulle virtue igieniche e medicinali della coca.
Milano, Autoservazione, 1859
51.
FREUD,S.: Uber Koka, Wiener zentralblatt fur die Gesamte
Therapie, 1884; 2:289-314.
52.
TORRES DE GALVIS,Y.: Current epidemiology and trends of cocaine
use and abuse: an international review. The WHO, Geneva,October
1990.
53.
GRINSPOON,L. & BAKALAR,J.: Cocaine, a drug and its social
evolution. Basic Books, Inc., Publishers, New York, 1976.
54.
SCOTT,P.D. & MARSHALL,J.: Cocaine politics. University of
California Press, Berkeley, 1991
55.
INCIARDI, J.A.: Letter, Int.J.Drug Policy, 1990, vol.1, nr 4 ,
blz. 26
56.
WALDORF,D., MURPHY,S., REINARMAN,C. & JOYCE,B. Doing coke: an
ethnography of cocaine users and sellers. 1977. Washington, D.C.,
Drug Abuse Council. MURPHY,S., REINERMAN,C. & WALDORF,D.: An
11 year follow-up of a network of cocaine users. British Journal
of Addictions, 1989; 84:427-436
57.
ERICKSON,P.: A longitudinal study of cocaine users: the natural
history of cocaine use and its consequences among Canadian
adults. Toronto, Addiction Research Foundation. Final report
NHRDP #6606-3929-DA, 1992.
58.
COHEN,P.& SAS,A.: Ten years of cocaine. Department of Human
Geography, University of Amsterdam, 1993
59.
BROWN,R. & MIDDLEFELL,R.: Fifty five years of cocaine
dependence. Br.J.Addictions 1989 vol. 84:8, 946.
60. New Scientist 17
nov. 1990
61.
KOSTEN, T.R. et al.: Desipramine and its 2-hydroxy-metabolite in
patiets taking or not taking methadone (letter) Am.J.Psychiatry
1990; 147(10):1379-1380.
62.
NEWCOMBE,R. & MATTHEWS,L.: Crack in Liverpool. Druglink,
sept. okt. 1989, blz.16.
63.
CHEUNG,Y.W.,ERICKSON,P.G. & LANDAU,T.C.: Experience of crack
use: findings from a community-based sample in Toronto. J.Drug
Issues, 1991; 21(1):121-140.
64.
MAHALIK et al.: Teratogenic potential of cocaine-hydrochloride in
CF-1 mice. J.Pharm. Sci. 1980;69:703-706
65.
ACKER et al.: Abruptio placentae associated with cocaine use. Am
J Obstet Gynecol 1983;146:220-221
66.
CHASNOFF,I.J., BURNS,W.J., SCHNOLL,S. & BURNS,K.A.: Cocaine
use in pregnancy, New England Journal of Medicine, 1985, 313 pp.
666-669
67.
CHASNOFF,I.J., BUSSEY,M.E., SAVICH,R. & STACK,C.M.: Perinatal
cerebral infarction and maternal cocaine use. Journal of
Pediatrics, 1986, 108: 456-459
68.
CHASNOFF,I.J. Perinatal effects of cocaine, Contemporary
Obstetrics and Gynecology, May 1987 pp 163-179
69.
CHASNOFF,I.J., BURNS,K.A. & BURNS,W.J.: Cocain use in
pregnancy: perinatal morbidity and mortality. Neurotoxicology and
Teratology, 1987; 161(9) pp. 291-293
70.
CHASNOFF,I.J., CHISUM,G.M. & KAPLAN,W.E.: Maternal cocaine
use and genitourinary tract malformations, Teratology 1988;
37:201-204
71.
CHASNOFF,I.J., GRIFFITH,D., MacGREGOR,S., DIRKES,K. &
BURNS,K.A.: Temporal patterns of cocaine use in pregnancy:
perinatal outcome. Journal of the American Medical Association,
1989; 261(12)pp. 1741-1744
72.
CHASNOFF,I.J., HUNT,C.E. & KAPLAN,D.: Prenatal cocaine
exposure is associated with respiratory pattern abnormalities.
American Journal of Diseases of Children, 1989; 143:583-587
73.
KOREN,G., GRAHAM,K., SHEAR,H. & EINARSON,T.: Bias against the
null hypothesis: the reproductive hazards of cocaine. Lancet
1989; no 8677, pp. 1440-1442
74.
FROMBERG,E.: Cocaine and pregnacy, hype or science; a review of
the literature. Background paper for meeting of WHO's Global
Advisory Committee on Cocaine, August 1992.
75.
LUTIGER,B., GRAHAM,K., EINARSON,T.R. & KOREN,G. (1991)
Relationship between gestational cocaine use and pregnancy
outcome: a meta-analysis. Teratology, 1991; 44(4) pp. 405-414.
76.
SHULGIN,A.: The narcotic pepper - the chemistry and pharmacology
of Piper methisticum and related species. Bull.Narc. 1973,
25(2):59-74.
77.
LEWIN 1927, cit. P.d'ABBS : Kava use in Arnhemland, the challenge
for policy. Internat.J.Drug Policy, 1991, 2(4).
78.
SCHOPEN,A.: Das Qat. Geschichte und Gebrauch des Genussmittels
Catha edulis (Forsk.) in der Arabischen Republik Jemen.
Wiesbaden, 1978.
79. KENNEDY,J.G.: The flower of paradise: the institutionalised
use of the drug qat in North Yemen. Reidel, Dordrecht, 1987.
80.
BIRKENHÄGER,T.K., BRUIJN,J.A., NOLEN,W.A. & VEGT,M.:
MAO-remmers als antidepressiva, een literatuuroverzicht
betreffende indicatiegebied en werkingsmechanisme. Tijdschrift
voor Psychiatrie, 1991, 33(7);445-462.
81.
GOLDMAN,M.J., GRINSPOON,L. & HUNTER-JONES,S.: Ritualistic use
of fluoxetine by a former substance abuser. Am.J.Psychiatry 1990,
147(10):1377
82.
STOLERMAN,I.: Nicotine on the brain. New Scientist, 3-11-1990;
33-35.
83.
HOFMANN,A. Structur und Synthese der Halluzinogene.
J.Mond.Pharm., 1970;13(3):187-205
84.
GARDNER,E.L. & LOWINSON,J.: Marijuana's interaction with
brain reward systems: update 1991. Pharmacology Biochemistry and
Behavior 1991;40:571-580.)
85.
MATHEW,R.J. & WILSON,W.H.: Acute changes in cerebral blood
flow after smoking marihuana. Life sciences, 1993; 52:757-767.
86.
ROBBE,H.W.J.: Influence of marihuana on driving.
Rijksuniversiteit Limburg, 1994.
87.
SHEDLER,J. & BLOCK,J. Adolescent drug use and psychological
health: a longitudinal inquiry. American psychologist, 1990,
45:612-630)
88.
GRINSPOON,L.: Marihuana reconsidered. Harvard University Press,
1971.
89.
GRINSPOON,L. & BAKALAR,J.B.: In: Lowinson et al.: Substance
abuse. A comprehensive textbook, pp 236-246. Raven press, New
York, 1992.
90.
GRINSPOON,L. & BAKALAR,J.B.: Marihuana, the forbidden
medicine. Yale University Press, New Haven, 1993.
91.
TUNVING,K., THUNLIN,S.O., RISBERG,j. & WARKENTIN,S.: Regional
cerebral bloodflow in long term heavy cannabis use. Psychiatry
research, 1986, 17:15-21.
92.
FARRE-ALBALADEJO,M.: Complicaciones neurologicas de las
toxicomanias. Archivos de Neurobiologia, 1989, 52
(suppl.I):143-148.
93.
FEHR,K. & KALANT,H.: Long-term effects of cannabis on
cerebral function: a review of the clinical and experimental
literature. In: Cannabis and health hazards. Proceedings of an
ARF/WHO meeting on adverse health and behavioral consequences of
Cannabis use. Toronto, 1983)
94.
KOLODNY,R.C., MASTERS,W.H., KOLODNY,R.M. & TORO,G.:
Depression of plasma testosterone levels after chronic intensive
marihuana use. New E.ng. J. Med. 1974, 290:872-874.
95.
BLOCK,R.I., FARINPOUR,R. & SCHLECHTE,J.A.: Effects of chronic
marijuana use on testosterone, luteinizing hormone, follicle
stimulating hormone, prolactin and cortisol in men and women.
Drug and Alcohol dependence, 1991; 28: 121-128.
96.
ZUCKERMAN,B., FRANK,D.A., HINGSON,R., AMARO,H., LEVENSON,S.M.,
KAYNE,H, PARKER,S., VINCI,R., ABOAGYE,K., FRIED,L.E., CABRAL,H.,
TIMPERI,R. & BAUCHNER,H. (1989) Effects of maternal marijuana
and cocaine use on fetal growth. New England Journal of Medicine,
320(12) pp. 762-768)
97.
FRIED,P.A., BUCKINGHAM,M. & VON KULMIZ,P.: Marihuana use
during pregnancy and perinatal risk factors. Am.J.Obstet.Gynecol.
1983,144:922-924.
98.
FRIED,P.A.,WATKINSON,B. & WILLAN,A.: Marihuana use during
pregnancy and decreased length of gestation. Am.J.Obstet.Gynecol.
1984;150:23-27.
99.
FRIED,P.A.: Cigarettes and marihuana: are there measurable long
ter neurobehavioral teratogenic effects? Neurotoxicology
1989;10:577-583.
100.
HOFFMAN,A.: LSD, my problem child. Tarcher, Los Angeles, 1983.
101.
STEVENS,J.: Storming heaven: LSD and the American dream. New
York, Atlantic Monthly Press, 1987.
102.
MARTIAL,DE MONTIGNY et al."LSD ou Lysergide: pharmacologie
et mecanismes d'action." Psychotropes 1988;4(3):7-11.
103. New Scientist
10-2-1983:367
104.
COWAN, Intern.J.Quantum Chemistry, vol.22 p 1059 ev.
105.
SILVERMAN: Research with psychedelics, Arch.Gen.Psychiat
1971;25:498-510.
106.
SMITH & SEYMOUR: J.Psych. Drugs 17(4) pag 298 1985).
107.
COHEN,S. & DITMAN,K.S.: Prolonged adverse reactions to LSD.
Arch.Gen.Psychiatr. 1963, vol.8.).
108.
FROMBERG.E.: Vondelparkproject 1972: verslag van de
hulpverlening.Stadhuis Amsterdam, 1972).
109.
COHEN,S.: Drug Abuse and Alcoholism vol VIII, no 2, 1979.
110.
COHEN,S.: LSD:The varieties of psychotic experience,
J.Psych.Drugs 17(4): 291-296 1985.
111.
AMAROSE & SCHUSTER: Arch.Gen.Psychiatr. 1971; 25:181-186.
112.
LEWIN,L.: Phantastica, 2e druk, Verlag G.Stilke, Berlin, 1927.
113.
HUXLEY,A.: The doors of perception. Chatto & Windus, 1954.
Heaven and hell. Chatto & Windus, 1956
114.
MERCK,E.: Verfahren zur Darstellung von
Alkyloxyaryldialyloxyaryl- und Alkylenedioxyarylaminopropanen
bzw. deren am Stickstoff monoalkylierten Derivaten. Duits patent
#274.350. 1914.
115.
HARDMAN,H.F.; HAAVIK,C.O. & SEEVERS,M.H.: Relationship of the
structure of mescaline and seven analogs to toxicity and behavior
in five species of laboratory animals. Toxicology and Applied
Pharmacology 1973; 25(2): 299-309.
116.
GASTON, T.R. & RASMUSSEN, G.T.: Identification of
3,4-Methylenedioxymetamphetamine. Microgram 1972; 5:60-63
117.
SHULGIN,A.T. & NICHOLS,D.E.: Characterization of three new
psychotomimetics. In: Stillman,R.C. & Willette,R.E. (Eds.)
The Pharmacology of hallucinogens. New York: Pergamon, 1978.
118.
GREER,G. & STRASSMAN,R.J.: Information on
"Ecstasy". Am.J.Psychiat. 1985; 142(11):1391
119.
GREER,G. & TOLBERT,R.: Subjective reports of the effects of
MDMA in a clinical setting. J. Psychoactive Drugs 1986,
18(4):319-327.
120.
SEYMOUR,R.B.: MDMA, another view of Ecstasy. Pharmchem Newsletter
1985; 14(3):1
121.
PEROUTKA,S.J.: Incidence of recreational use of
3,4-methylenedioxy-methamfetamine (MDMA,Extacy) on an
undergraduate campus. N.Engl.J.Med.; 1987; 317: 1542-1543.
122.
FROMBERG,E. & JANSEN,F.: Het Drug Informatie en Monitoring
Systeem, verslag sept.'92-juni '93. NIAD, Utrecht, 1993.
123.
SHULGIN,A.: Some qualitative properties of the psychotomimetics.
Neurosciences Research Progress Bulletin 1970, 8(1):72-78
124.
SHULGIN,A. & SHULGIN,A.: PIHKAL. Transform press, Berkeley,
1991
125.
KLEIN,J.: The new drug they call Ecstasy. **New York, May
20,1985.
126.
DOWNING,J.: The psychological and physiological effects of MDMA
on normal volunteers. J.Psychoactive Drugs, 1986, 18(4): 335-340.
127.
HAYNER, G.N. & McKINNEY, M.C.: The dark side of ecstacy.
J.Psychoactive Drugs, 1986, vol.18(4): 341-347.
128.
SEYMOUR,R.B.: MDMA, another view of Ecstasy. Pharmchem
Newsletter, 1985, 14(3):1.
129.
WOLFSON,P.E.: Meetings at the edge with Adam: a man for all
seasons. J. of Psychoactive Drugs, 1986, vol. 18 (4):329-333
130.
DE LOOR,A.: De drug XTC bestaat niet. Adviesburo Drugs,
Amsterdam, 1989.
131.
VEREBEY,K.,ALRAZI,J. & JAFFE,H.: The complications of
"Ecstasy". JAMA, 1988; 259:1649-1650
132.
BROWN,C. & OSTERLOH,J.: Multiple severe complications from
recreational ingestion of MDMA ("Ecstasy"). JAMA 1987;
258: 780-781.
133.
BRUSSEL,G.H.A.van,: XTC, een nieuwe softdrug. Ned.Tijdschrift v
Geneeskunde: 1991, 135(44): 2062-2063
134.
CREIGHTON,F.J., BLACK,D.L.& HYDE,C.E.: Ecstasy psychosis and
flashbacks; British Journal of Psychiatry 1991, 159(11):713-715)
135.
DOWLING,G.P.,McDONOUGH,E.T.& BOST,R.O.: "Eve" and
"Ecstasy", a report of five deaths associated with the
use of MDEA and MDMA. JAMA, 1987; 257(12): 1615-1617.
136.
HENRY,J.A., JEFFREYS,K.J. & DAWLING,S.: Toxicity and deaths
from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992;
340:384-387
137.
MAN,R.A.de, WILSON,J.H.P. & TJEN,H.S.L.M.: Acuut lever-falen
door methyleendioxymetamfetamine ('ecstasy'); NTVG 1993; 137(14):
727-729
138.
McGUIRE,P. & FAHY,T.: Chronic paranoid psychosis after misuse
of MDMA ('ecstasy"); BMJ, 1991, 302(6778):697
139.
SCHIFANO,F.: Chronic atypical psychosis associated with MDMA
('ecstasy') abuse; Lancet 1991, 338:1335
140.
SCREATON,G.R., SINGER,M., CAIRNS,H.S., THRASHER,A., SARNER,M.
& COHEN,S.L. Lancet, 1992,339: 677-678
141.
VEREBEY,K. & ALRAZI,J. & JAFFE,H.: The complications of
"Ecstacy" (MDMA). JAMA, 1988; 259: 1649-1650.
142.
WHITAKER-AZMITIA,P.M. & ARONSON,T.A.: "Ecstasy"
(MDMA)-induced panic. Am.J.Psychiatry, 1989; 146(1): 119.
143.
WINSTOCK,A.R.: Chronic paranoid psychosis after misuse of MDMA;
British Medical Journal, 1991, 302(6785):1150-1151
144.
GINZBERG,M.D., HERTZMAN,M. & SCHMIDT-NOWARA,W.W.: Amphetamine
intoxication with coagulopathy, hypertehermia and reversible
renal failure. Annals of Int.Med. 1970;73:81-85.
145.
RICAURTE,G.A., FORNO,L.S., WILSON,M.A., DELANNEY,L.E., IRWINI.,
MOLLIVER, M.E. & LANGSTON,J.:
3,4-Methylenedioxy-metamfetamine selectively damages central
serotonergic neurons in non-human primates. JAMA; 1988; 260(1):
51-55
146.
PRICE,L.H., RICAURTE,G.A.,KRYSTAL,J.H.& HENIGER,G.R.:
Neuroendocrine and moodresponses to intravenous l-tryptophan in
3,4-methylenedioxymetamfetamine (MDMA) users. Arch.General
Psychiatry, 1989, 46:20-22
147.
McCANN,U.& RICAURTE,G.: presentation on the 1993 Annual
Meeting of the Society for Neuroscience.
148.
NICHOLS,D.E.: Differences between the mechanism of action of
MDMA, MBDB and the classic hallucinogens. Identification of a new
therapeutic entactogen class. J.Psychoactive Drugs, 1986;
18(4):305-313
149.
EMBODEN,W.: Narcotic plants. Studio Vista, London,1972
150.
Editorial: Ketamine a new anaesthetic. British Medical Journal
19-6-1971, pag. 666.
151.
RAINEY,J.M. & CROWDER,M.K.: Ketamine or phencyclidine
(letter). JAMA, 1974, 230(6): 824
152.
Editorial: Phencyclidine, the new american street drug. British
Medical Journal 1980;281:1511.
153.
Various authors: J.Psychedelic drugs: 1980; 12(3&4):181-335
154.
FROMBERG.E.: De samenstelling van illegale drugs in Nederland,
Stichting DrugInformatie, Amsterdam, 1973
155.
SHAPIRO,H.: Ketamine factsheet. Druglink 1992; 7(3):7
DrugTexT
Web-Lab (C)1995 mario lap